In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.
March 2026 in “Skin Appendage Disorders” In this study, among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, 1.33% developed scarring alopecia, all being female, with alopecia not impacting their cancer treatment continuation and a favorable cancer outcome reported.
14 citations
,
February 2023 in “Frontiers in immunology” This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.
November 2020 in “Journal of The American Academy of Dermatology” This study examined dermoscopic features in African-American women with different types of alopecia and found that a perifollicular pink blush, potentially indicating inflammation, was common, particularly resolved with anti-inflammatory treatment, suggesting dermoscopy could aid in management.
6 citations
,
January 2019 in “Journal of dermatology” This letter to the editor discusses immune checkpoint inhibitor-related alopecia and insights into its pathophysiology using non-invasive diagnostic techniques, but reports no new clinical results.